PHIO PHARMACEUTICALS CORP. - COMMON STOCK

Phio Pharmaceuticals Secures New Investor

17 مايو 2024 09:00:56 بحسب Nasdaq GlobeNewswire

Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)

16 مايو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study

15 مايو 2024 13:00:00 بحسب Nasdaq GlobeNewswire

Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update

09 مايو 2024 17:25:39 بحسب Nasdaq GlobeNewswire

Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)

30 أبريل 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells

22 أبريل 2024 13:10:09 بحسب Nasdaq GlobeNewswire

Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)

16 أبريل 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)

11 أبريل 2024 07:30:00 بحسب Nasdaq GlobeNewswire

National Spotlight Features Phio’s Innovative RNAi Technology Platform

03 أبريل 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update

02 أبريل 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

21 مارس 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research

13 مارس 2024 14:00:25 بحسب Nasdaq GlobeNewswire

Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders

06 مارس 2024 10:30:59 بحسب Nasdaq GlobeNewswire

Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

31 يناير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds

07 ديسمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

09 نوفمبر 2023 16:30:20 بحسب Nasdaq GlobeNewswire

Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas

09 نوفمبر 2023 07:30:00 بحسب Nasdaq GlobeNewswire

Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control

03 نوفمبر 2023 12:00:00 بحسب Nasdaq GlobeNewswire

Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

12 أكتوبر 2023 11:00:00 بحسب Nasdaq GlobeNewswire

Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL™ Compound PH-894

11 أكتوبر 2023 07:30:19 بحسب Nasdaq GlobeNewswire